Literature DB >> 24971479

Role of miR-15/16 in CLL.

Y Pekarsky1, C M Croce1.   

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The most common chromosomal abnormalities detectable by cytogenetics include deletion at 13q (55%), 11q (18%), trisomy 12 (12-16%) and 17p (8%). In 2002, we discovered that a microRNA cluster miR-15a/miR-16-1 (miR-15/16) is the target of 13q deletions in CLL. MicroRNAs encoded by the miR-15/16 locus (miR-15 and miR-16) function as tumor suppressors. Expression of these miRNAs downregulated in CLL, melanoma, colorectal cancer, bladder cancer and other solid tumors. miR-15/16 cluster targets multiple oncogenes, including BCL2, Cyclin D1, MCL1 and others. The most important target of miR-15/16 in CLL is arguably BCL2, as BCL2 is overexpressed in almost all CLLs. In this review, we discuss the discovery, functions, clinical relevance and treatment opportunities related to miR-15/16.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24971479      PMCID: PMC4262785          DOI: 10.1038/cdd.2014.87

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  47 in total

Review 1.  BAFF AND APRIL: a tutorial on B cell survival.

Authors:  Fabienne Mackay; Pascal Schneider; Paul Rennert; Jeffrey Browning
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 2.  MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.

Authors:  Victor Ambros
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.

Authors:  S Stilgenbauer; J Nickolenko; J Wilhelm; S Wolf; S Weitz; K Döhner; T Boehm; H Döhner; P Lichter
Journal:  Oncogene       Date:  1998-04-09       Impact factor: 9.867

4.  An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells.

Authors:  R Berland; H H Wortis
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

5.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

Authors:  S Kitada; J Andersen; S Akar; J M Zapata; S Takayama; S Krajewski; H G Wang; X Zhang; F Bullrich; C M Croce; K Rai; J Hines; J C Reed
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

6.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

7.  TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival.

Authors:  S Y Lee; A Reichlin; A Santana; K A Sokol; M C Nussenzweig; Y Choi
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

8.  Differential effects of Bcl-2 on T and B cells in transgenic mice.

Authors:  M Katsumata; R M Siegel; D C Louie; T Miyashita; Y Tsujimoto; P C Nowell; M I Greene; J C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

Review 9.  Cell cycle deregulation in B-cell lymphomas.

Authors:  Margarita Sánchez-Beato; Abel Sánchez-Aguilera; Miguel A Piris
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

10.  TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice.

Authors:  Juan M Zapata; Maryla Krajewska; Herbert C Morse; Yongwon Choi; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-15       Impact factor: 11.205

View more
  70 in total

1.  Chronic lymphocytic leukemia: looking into the dark side of the genome.

Authors:  R Valdés-Mas; J Gutiérrez-Abril; X S Puente; C López-Otín
Journal:  Cell Death Differ       Date:  2015-11-27       Impact factor: 15.828

2.  MicroRNAs--getting the hang of it.

Authors:  A H Lund
Journal:  Cell Death Differ       Date:  2015-01       Impact factor: 15.828

3.  MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer.

Authors:  Danyi Zhao; Yang Zhang; Lei Song
Journal:  Pathol Oncol Res       Date:  2017-06-30       Impact factor: 3.201

4.  MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene.

Authors:  Christopher Alderman; Ayoub Sehlaoui; Zhaoyang Xiao; Yixin Yang
Journal:  Tumour Biol       Date:  2016-08-04

5.  Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.

Authors:  Korosh Ashrafi Dehkordi; Morteza Hashemzadeh Chaleshtori; Mohamadreza Sharifi; Ali Jalili; Fardin Fathi; Daem Roshani; Bahram Nikkhoo; Mohammad Saeed Hakhamaneshi; Mohammad Reza Mahmoodian Sani; Mahboue Ganji-Arjenaki
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

Review 6.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

7.  Downregulated miR-621 promotes cell proliferation via targeting CAPRIN1 in hepatocellular carcinoma.

Authors:  Yao Zhang; Wei You; Haoming Zhou; Zhiqiang Chen; Guoyong Han; Xueliang Zuo; Long Zhang; Jindao Wu; Xuehao Wang
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

8.  The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Authors:  M Abraham; S Klein; B Bulvik; H Wald; I D Weiss; D Olam; L Weiss; K Beider; O Eizenberg; O Wald; E Galun; A Avigdor; O Benjamini; A Nagler; Y Pereg; S Tavor; A Peled
Journal:  Leukemia       Date:  2017-03-10       Impact factor: 11.528

Review 9.  Exploiting microRNAs As Cancer Therapeutics.

Authors:  Tamsin Robb; Glen Reid; Cherie Blenkiron
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

10.  Technological advances in precision medicine and drug development.

Authors:  Elaine Maggi; Nicole E Patterson; Cristina Montagna
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.